Peter Lichtlen, MD, PhD, BBA
Peter Lichtlen is the Chief Medical Officer at Sucampo Pharmaceuticals Inc. a Nasdaq-listed biopharmaceutical company located in Bethesda (USA), Zug (Switzerland) and Osaka (Japan). In his role he oversees both clinical development and Medical Affairs of the company’s pipeline projects and product portfolio on a global basis. He also has a leading role in the company’s interactions with regulatory agencies across the globe related to CTAs/INDs and marketing authorization applications. He has also successfully managed reimbursement negotiations with reimbursement agencies such as UK NICE. Prior to joining Sucampo, Peter held various roles of increasing responsibility at ESBATech AG (acquired by Alcon/Novartis in 2009), of Schlieren, Switzerland, which he joined in 2000. At ESBATech, Peter served as Medical Director/Head, Clinical Research and Development, and a member of its senior management team, from 2004 to 2010. Peter’s focus in terms of pharmaceutical product development has been in ophthalmology, gastrointestinal diseases and rheumatology, with exposure to projects in other therapeutic areas as well.
Peter also co-founded Numab AG, a Swiss biotechnology company that innovates antibody-based therapeutics, where he also serves a member of the Board of Directors. Peter is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of several patents. Peter earned doctorate degrees in medicine and molecular biology at the University of Zurich and holds a bachelor degree in business administration.”
Jean-Philippe Combal, PharmD, PhD
Jean-Philippe Combal, Pharm.D., Ph.D from Paris University is currently Chief Operating Officer at GenSight Biologics, a clinical stage gene therapy company for treating blindness. He has been managing preclinical and clinical product and portfolio development in Ophthalmology at Fovea Pharmaceuticals/Sanofi serving as Vice President, Director of Development at Fovea, and then held the position of Vice President, Strategic Marketing for the Ophthalmic Division at Sanofi. Jean-Philippe’s expertise reside in defining, developing new & innovative drugs for various therapeutic indications including more recently ophthalmology and previously dermatology et Galderma International S.A. as Strategic Therapeutic Area leader. The synergy of global drug & strategic marketing development combined with business experience bring value for portfolio development of our technologies in various therapeutic area analyses.
Francine Behar-Cohen, MD, PhD
Dr. Francine Behar-Cohen is currently Chief of the ophthalmology unit and Medical Director at the Jules-Gonin hospital in Lausanne. Previously she has served as professor and staff ophthalmologist at the Hôtel-Dieu de Paris. A retinologist, Dr. Behar-Cohen received her M.D. and a Ph.D. in cellular biology from the Paris-Descartes University and did her internship in Paris hospitals and her residency in vitreoretinal surgery at the Hôtel-Dieu de Paris. In 2001, Dr. Behar-Cohen headed an Avenir team at France’s national institute of health and medical research (INSERM,) and in 2003 she founded INSERM Unit 598, dedicated to the physiopathology of eye diseases and therapeutic innovations. In 2008, this unit became the Cordelier Research Center, located in Paris. Dr. Behar-Cohen has been researching ocular drug delivery systems and pharmacology for more than ten years. She is also investigating intraocular inflammation and the role of inflammation in retinal pathologies previously considered noninfl ammatory—including ADM and diabetic retinopathy. She is the author of more than 110 publications and about a dozen books or book chapters.